The headline comparison
| Attribute | Ozempic | Wegovy |
|---|---|---|
| Active molecule | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Dose range | 0.25-1.0mg weekly | 0.25-2.4mg weekly |
| TGA indication | Type 2 diabetes mellitus | Chronic weight management (BMI ≥30, or ≥27 with comorbidity) |
| PBS subsidised? | Yes (T2D only) | No |
| PBS price | $31.60 general / $7.70 concession | N/A |
| Private cost/month | $380-$450 | $420-$530 |
| Telehealth bundle | $290-$420/month | $290-$450/month |
| Trial weight loss | ~10-12% (1mg dose) | ~15% (2.4mg dose, 68 weeks) |
| Side effect profile | GI symptoms common during titration | Similar pattern; higher doses can be more pronounced |
Why are they branded as two different drugs?
Novo Nordisk created two distinct brands for the same molecule to match regulatory pathways. Ozempic was developed and approved first (2017 in the US, 2019 in Australia) for type 2 diabetes, the established commercial indication. Wegovy followed (2021 US, 2023 Australia) at higher doses, specifically targeting obesity as a distinct chronic condition.
Why the distinction matters: regulatory bodies treat them differently. PBS subsidy follows the TGA-approved indication. Insurance reimbursement (in countries with private insurance) follows the same logic. Prescribing decisions differ based on which condition you’re treating.
Which should YOU take? Three decision pathways
Pathway A: You have type 2 diabetes
Choose Ozempic. PBS Authority Streamlined gets you the medication at $31.60/month (general) or $7.70/month (concession) if you meet criteria. Check your PBS eligibility in our 5-question decision tree. Wegovy offers no clinical advantage over Ozempic for T2D and costs 14x more.
Pathway B: You have obesity + type 2 diabetes
Choose Ozempic. The semaglutide mechanism treats both conditions. PBS Authority covers the medication if your HbA1c meets threshold. You get GLP-1 weight loss benefit "for free" alongside the diabetes management.
Pathway C: You have obesity without diabetes
Discuss Wegovy vs off-label Ozempic with your prescriber. Wegovy is the on-label, evidence-supported choice (higher dose, different weight-change range in trials). Off-label Ozempic is a legitimate alternative, slightly cheaper but capped at 1.0mg dose. Read our pathway guide.
The off-label Ozempic decision
A significant proportion of Ozempic prescriptions in Australia are off-label for weight loss. This is legitimate clinical practice supported by the STEP trial evidence. The PBS won’t subsidise it (no Authority code without T2D diagnosis), so you pay private price.
The trade-off: off-label Ozempic is ~$40-80/month cheaper than Wegovy, but you cap at 1.0mg dose vs Wegovy's 2.4mg. The 0.5-1.0mg dose is sufficient for many patients seeking moderate weight loss (5-10%). Patients pursuing 15%+ weight loss typically need Wegovy's higher dose to achieve trial-equivalent results.
Supply availability considerations
Both medications have had global supply constraints. Ozempic supply has been more affected by off-label demand. Wegovy supply varies by dose strength. Practical advice:
- Check pharmacy stock before committing to a programme
- Telehealth providers usually have allocation visibility
- If Wegovy is short at your dose, your prescriber may flex you to off-label Ozempic temporarily
- Bring a backup plan: which alternative will you switch to if your first choice goes out of stock?
Compare your real out-of-pocket cost
Our GLP-1 switch cost calculator models 12-month and 24-month costs for Ozempic, Wegovy and Mounjaro, including dose escalation, consultation fees, and telehealth vs retail pharmacy comparisons.